Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. - Wikidata - awgldk - TriplyDB

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.

http://www.wikidata.org/entity/Q33395251

about

Atypical hemolytic uremic syndrome Critical appraisal of eculizumab for atypical hemolytic uremic syndrome Advances and challenges in the management of complement-mediated thrombotic microangiopathies Complement cascade and kidney transplantation: The rediscovery of an ancient enemy Current treatment of atypical hemolytic uremic syndrome Eculizumab: a review of its use in atypical haemolytic uraemic syndrome Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein.Clinical grand rounds: atypical hemolytic uremic syndrome.A time for reappraisal of "atypical" hemolytic uremic syndrome: should all patients be treated the same?Thrombotic microangiopathy and associated renal disorders.Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.STEC-HUS, atypical HUS and TTP are all diseases of complement activation.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.Complement disorders and hemolytic uremic syndrome.Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series.The use of eculizumab in renal transplantation.Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.Dynamics of complement activation in aHUS and how to monitor eculizumab therapy Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature End-stage renal disease from hemolytic uremic syndrome in the United States, 1995-2010 Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in China New immunosuppressive agents in pediatric transplantation.The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents.Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.Primary disease recurrence—effects on paediatric renal transplantation outcomes.Targeting the complement cascade: novel treatments coming down the pike.Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management.Gemcitabine induced hemolytic uremic syndrome.Treatment of atypical uraemic syndrome in the era of eculizumab Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

P2860

Q21202864-4227C6A2-129E-4610-9475-534374EDD7FC Q26750692-480703FB-1149-47FE-96D1-971B5B06D88A Q26796453-6048B9E3-0E17-4322-9817-EB356C0DD6B4 Q26829790-E1F8E1E3-81CB-48A3-B6FE-52108D5DB8DB Q27003211-56D1A595-6431-41F5-AAD8-4519E6B407FE Q28302228-BE67B0F1-7CA2-4DE0-BDCB-450A930E2ECF Q33396908-BF02C9DA-620A-4C4A-A73A-950140191F81 Q33400211-5AF47D8E-BCF4-456A-B694-85EA80B94FA8 Q33400705-35CF72F6-C3A8-4041-A166-060491887AB2 Q33400834-41EBDE59-9325-446A-9145-F5263D68243E Q33401658-66AB1011-53C9-419A-8506-9BDA49142A46 Q33402372-A1359404-5AAB-485A-9545-78F88927A544 Q33403196-6DB07B90-4F60-4D5F-975B-7A21C6334E38 Q33403359-9D070A7F-6B41-4A25-8F4C-79E2304E0ACC Q33403607-A0259021-090E-442D-AF04-B60BFCD189E0 Q33405522-DE689E9D-DDAF-4EA0-B8B2-BCBAAF77DF75 Q33405802-818EBA46-5804-4B23-B33E-D2957CBEBB2D Q33406251-1ADDFF32-C5B8-4E8F-9E9E-34824BB26F87 Q33406570-A91947AA-D217-42D8-9039-BE70D6901808 Q33408171-8AB466D2-E22E-4A70-82DE-253B0A6BDE38 Q33408733-EC89DA88-80C0-406A-81C4-89BBD3213744 Q33415471-69E58F50-E7B6-4139-A204-EBA1210004CA Q33415937-ED1C9E26-59FF-4079-953D-ADD498AB11DD Q33416519-7FDFF790-2467-4413-96ED-70AA86978104 Q33419812-1BCD533A-D207-4C11-A47C-FD264EDFEEA3 Q33420509-051B13ED-4E75-45F4-BE85-3DDB1164C21F Q33424946-40B2EADB-BAF3-441E-962F-B8FC0EA6A22D Q33430817-6F560C4E-FD44-433F-BCC4-6DCF1A7BFBCA Q33432544-F0FBD0AE-1DD3-4055-993B-DF5A90E33AEC Q37446883-60312E80-96B8-4984-8219-19978A3216FA Q38063962-EE3A2B4E-B6B4-4156-879C-01EEAB8A618B Q38118112-8D52BC7F-D9B1-4673-86A6-55936E024B9D Q38445275-3C5D91D8-712B-4AF8-A7A0-FB57385C0F09 Q38850489-07539208-D665-4E70-8CCF-37DC80660345 Q39112532-68DC2D76-9B05-49B1-8481-5FD08E72DA85 Q39569221-0B5666F0-8C0C-4100-9650-DFCBD3DEC982 Q39719068-3D691348-CCE2-444F-A24C-8AE1A3BC31C0 Q40096366-1A8438B6-3BA8-4547-B661-62740FFB78F0 Q40654455-D42708C5-1EFE-4A73-8CA2-3DC6FF9C3874 Q42086661-F7A886A7-D3C7-462B-9875-FA364F99445C

P2860

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.

http://www.wikidata.org/entity/Q33395251

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prophylactic eculizumab prior ...... cal hemolytic uremic syndrome.

@ast

Prophylactic eculizumab prior ...... cal hemolytic uremic syndrome.

@en

type

label

Prophylactic eculizumab prior ...... cal hemolytic uremic syndrome.

@ast

Prophylactic eculizumab prior ...... cal hemolytic uremic syndrome.

@en

prefLabel

Prophylactic eculizumab prior ...... cal hemolytic uremic syndrome.

@ast

Prophylactic eculizumab prior ...... cal hemolytic uremic syndrome.

@en

P1433

Q33395251-4F215024-5D51-4D0A-840E-00EF87288674

P1476

Q33395251-4CFFF082-F45D-40CD-A1C9-515164DC9203

P2093

Q33395251-06862762-B985-4F01-B808-CFD919184996

Q33395251-496DECE6-F5C8-4DA5-85DF-00DBD2A9EA08

Q33395251-49B41592-4BCF-4823-A789-E89E1B20FDF0

Q33395251-82AB4102-BFB2-47CB-B898-93D794BC339D

Q33395251-F8F36DA4-5D99-499E-B4A8-7DBDCA4E6B33

P2860

Q33395251-00F0A83C-E29E-4A9D-8CDE-7217A13F6F2B

Q33395251-06C7F1CF-9243-4560-8D82-08F66EE8FC53

Q33395251-0858D450-1AF7-42F1-A9F4-6435E4B6AA09

Q33395251-0D19B643-72ED-48AA-BFA6-8EE246D28CCE

Q33395251-133762C4-2D59-497D-BFDD-B12D11467FD5

Q33395251-2EE3014B-1A95-461C-AEBE-62F3425F6958

Q33395251-44341C90-A5C2-4CBA-868B-EF4F393A6E77

Q33395251-51966527-323A-46C9-BF42-7F5F4ED07F3A

Q33395251-55A66D3B-4793-465C-B4DE-6511CFA30280

Q33395251-6518F99E-3792-4688-BA46-73AEA5F7DA34

P2888

Q33395251-DD0FCC47-71A4-4AF9-8E88-AD29FB7FC054

P304

Q33395251-62C2B8A7-7D8A-4E1A-943D-06517405750B

P31

Q33395251-B0036674-EFB1-42BF-AF85-C775C2B9EADB

P356

Q33395251-28F7F8E1-FF81-4035-BBF9-7110441B20E1

P433

Q33395251-0CD6C8F9-2384-4904-BC97-A6B61DE3A620

P478

Q33395251-17926B77-A041-4CD4-960B-66299E068FC0

P577

Q33395251-0C6B8E6E-EE46-4D46-AE87-5BF489B2624E

P6179

Q33395251-1980A6AB-EC6B-45A9-BE0F-D477252791E8

P698

Q33395251-0C5B8564-BF6C-4FB7-B17C-553CE46DFAAC

P356

S00467-011-1879-9

P1433

Pediatric Nephrology

P1476

Prophylactic eculizumab prior ...... cal hemolytic uremic syndrome.

@en

P2093

Alfred Koenigsrainer

http://www.w3.org/2001/XMLSchema#string

Dirk Bassler

http://www.w3.org/2001/XMLSchema#string

Marcus Weitz

http://www.w3.org/2001/XMLSchema#string

Oliver Amon

http://www.w3.org/2001/XMLSchema#string

Silvio Nadalin

http://www.w3.org/2001/XMLSchema#string

P2860

Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients

Infectious diseases associated with complement deficiencies.

Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir.

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Atypical hemolytic-uremic syndrome.

Transplantation in atypical hemolytic uremic syndrome.

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].

P2888

s00467-011-1879-9

P304

1325-1329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00467-011-1879-9

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1022828398

http://www.w3.org/2001/XMLSchema#string

P698

21556717

http://www.w3.org/2001/XMLSchema#string